V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004178 | 330002057 | null | null | Curative (C) | 2015-08-24 | 2015-08-31 | CETUXIMAB | null | N | 330016499 | CETUXIMAB |
| 330004180 | 330002059 | 1.79 | 66.8 | Neo-adjuvant (N) | 2014-11-17 | 2014-11-24 | EURAMOS TRIAL | N | N | 330016511 | EURAMOS TRIAL |
| 330004181 | 330002060 | 1.68 | 85 | Curative (C) | null | 2015-01-03 | Cyclophosphamide + Dex + Rituximab | N | N | 330016512 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004182 | 330002061 | 1.79 | null | Neo-adjuvant (N) | 2013-01-30 | 2013-02-11 | EURAMOS TRIAL | N | N | 330016514 | EURAMOS TRIAL |
| 330004183 | 330002061 | 1.76 | 108 | Curative (C) | 2016-09-24 | 2016-10-02 | EW EuroEwing 2012 Arm A VIDE | 02 | N | 330016514 | EURO-EWING |
| 330004184 | 330002062 | 1.74 | 82.5 | Curative (C) | 2017-09-28 | 2017-10-17 | Cetuximab + Radiotherapy Load | null | Y | 330016526 | CETUXIMAB + RT |
| 330004186 | 330002064 | 1.77 | 59 | Curative (C) | 2015-09-09 | 2015-09-20 | MAP | N | N | 330016543 | MAP |
| 330004187 | 330002064 | 1.65 | 100 | Neo-adjuvant (N) | 2016-01-20 | 2016-01-20 | EW EuroEwing 2012 Arm A VIDE | 02 | null | 330016543 | EURO-EWING |
| 330004188 | 330002064 | 1.77 | 47.8 | Palliative (P) | 2018-05-03 | 2018-05-03 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | 330016543 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004189 | 330002064 | 1.87 | 82 | Not known (9) | 2016-04-22 | 2016-05-05 | CVP R | N | N | 330016543 | CVP R |
| 330004190 | 330002064 | 1.62 | 57.6 | Curative (C) | 2013-10-23 | 2013-10-26 | CETUXIMAB + RT | null | null | 330016543 | CETUXIMAB + RT |
| 330004191 | 330002065 | 1.55 | 74.4 | Disease modification (D) | 2017-09-27 | 2017-10-11 | Cyclophosphamide + Dex + Rituximab | N | N | 330016578 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004192 | 330002066 | 1.47 | 32 | Curative (C) | 2014-01-30 | 2014-01-31 | CETUXIMAB | 02 | N | 330016580 | CETUXIMAB |
| 330004193 | 330007128 | 0 | 44 | Palliative (P) | 2017-03-05 | 2017-03-06 | CISPLATIN + ETOPOSIDE | 2 | N | 330016585 | CISPLATIN + ETOPOSIDE |
| 330004194 | 330002067 | 1.69 | 60.8 | Curative (C) | 2017-12-18 | 2017-12-21 | PAM | 2 | N | 330016588 | MAP |
| 330004195 | 330002067 | 1.76 | 62 | Curative (C) | 2017-09-02 | 2017-09-08 | PAM x 2 pre-surgery (cycles 1&2) | N | N | 330016588 | MAP |
| 330004196 | 330002068 | null | null | Curative (C) | 2016-02-01 | 2016-02-08 | CVP R | N | null | 330016600 | CVP R |
| 330004197 | 330002068 | 1.79 | 51.4 | Neo-adjuvant (N) | 2013-04-02 | 2013-04-02 | OST Euramos 1 Closed Trial - AP | N | N | 330016600 | MAP |
| 330004198 | 330002069 | 1.73 | 56.2 | Neo-adjuvant (N) | 2015-10-06 | 2015-10-16 | Dox + HD Mtx (post PAM) | N | N | 330016615 | DOXORUBICIN + HD MTX |
| 330004199 | 330002069 | 1.89 | 70.9 | null | 2016-10-13 | 2016-10-18 | CAP | N | N | 330016615 | CAP |
| 330004200 | 330002069 | 1.64 | 58.4 | Neo-adjuvant (N) | 2014-06-16 | 2014-06-16 | EW EuroEwing 2012 Arm A VIDE | 2 | N | 330016615 | EURO-EWING |
| 330004201 | 330002070 | 0 | 26 | Palliative (P) | 2015-12-25 | 2016-01-16 | CVP R | N | N | 330016625 | CVP R |
| 330004202 | 330002071 | 1.77 | 35.4 | Neo-adjuvant (N) | 2014-12-10 | 2014-12-31 | MAP | N | N | 330016630 | MAP |
| 330004203 | 330002071 | 1.78 | 63.2 | Adjuvant (A) | 2015-10-10 | 2015-10-31 | Cetuximab + Radiotherapy Maint | N | Y | 330016630 | CETUXIMAB + RT |
| 330004204 | 330002072 | 0 | 78.8 | Neo-adjuvant (N) | 2013-10-23 | 2013-11-26 | Dox + HD Mtx (post PAM) | N | N | 330016636 | DOXORUBICIN + HD MTX |
| 330004205 | 330002072 | 1.67 | null | Adjuvant (A) | 2013-06-22 | 2013-07-10 | CVP R | N | N | 330016636 | CVP R |
| 330004206 | 330002073 | 1.79 | 103 | Curative (C) | null | 2016-03-09 | Cetuximab + Radiotherapy Load | null | null | 330016649 | CETUXIMAB + RT |
| 330004207 | 330002074 | 1.6 | 45.3 | Palliative (P) | 2013-03-09 | 2013-03-13 | CISPLATIN + ETOPOSIDE | 2 | null | 330016650 | CISPLATIN + ETOPOSIDE |
| 330004208 | 330002074 | 1.65 | 57 | Curative (C) | 2013-08-28 | 2013-09-19 | CETUXIMAB + RT | N | Y | 330016650 | CETUXIMAB + RT |
| 330004209 | 330002074 | 1.7 | 60 | Not known (9) | 2013-09-10 | 2013-09-23 | CARBOPLATIN + GEMCITABINE | N | N | 330016650 | GEMCARBO |
| 330004210 | 330002075 | 1.8 | 62 | Palliative (P) | 2017-05-06 | 2017-05-28 | Cisplatin + Etoposide (3 day) | N | N | 330016666 | CISPLATIN + ETOPOSIDE |
| 330004211 | 330002076 | 1.78 | 69.5 | Curative (C) | null | 2016-01-01 | CETUXIMAB + RT | N | Y | 330016667 | CETUXIMAB + RT |
| 330004212 | 330007135 | 1.8 | 80 | Curative (C) | 2016-05-21 | 2016-05-25 | EURO-EWING | 02 | N | 330016671 | EURO-EWING |
| 330004213 | 330007135 | 1.79 | 80 | Curative (C) | 2016-01-18 | 2016-01-25 | PAM x 2 pre-surgery (cycles 1&2) | 2 | N | 330016671 | MAP |
| 330004214 | 330007135 | null | 65.9 | Palliative (P) | 2016-11-18 | 2016-11-23 | GemCarbo Days 1+8 | N | N | 330016671 | GEMCARBO |
| 330004215 | 330007135 | 1.67 | 51.8 | Palliative (P) | 2013-10-04 | 2013-11-08 | Cetuximab 7 day (Cycle 1) | N | Y | 330016671 | CETUXIMAB |
| 330004216 | 330007135 | 1.84 | 56.6 | null | 2018-02-23 | 2018-02-27 | GemCarbo Days 1+8 | N | N | 330016671 | GEMCARBO |
| 330004217 | 330002077 | 1.67 | 61.8 | Palliative (P) | 2016-06-19 | 2016-06-25 | Cisplatin + Etoposide po&iv 3 day | N | N | 330016692 | CISPLATIN + ETOPOSIDE |
| 330004218 | 330002078 | 1.74 | 71.6 | Curative (C) | 2016-07-12 | 2016-07-18 | EURAMOS TRIAL | 2 | N | 330016697 | EURAMOS TRIAL |
| 330004221 | 330009867 | 1.43 | 87.2 | Palliative (P) | 2013-08-12 | 2013-08-17 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330016720 | CISPLATIN + GEMCITABINE |
| 330004222 | 330002080 | 1.58 | 52.4 | Neo-adjuvant (N) | 2016-12-06 | 2016-12-10 | CISPLATIN + ETOPOSIDE | 02 | N | 330016723 | CISPLATIN + ETOPOSIDE |
| 330004223 | 330002080 | 1.82 | 69.8 | Curative (C) | 2015-11-29 | 2016-02-07 | MAP | N | N | 330016723 | MAP |
| 330004224 | 330002080 | 1.76 | 52 | Curative (C) | 2016-06-19 | 2016-07-03 | CISPLATIN + ETOPOSIDE | 02 | N | 330016723 | CISPLATIN + ETOPOSIDE |
| 330004225 | 330002081 | null | 28.1 | Neo-adjuvant (N) | 2017-03-23 | 2017-03-23 | Dox + HD Mtx (post PAM) | N | N | 330016728 | DOXORUBICIN + HD MTX |
| 330004226 | 330007138 | 1.66 | 111.3 | Curative (C) | null | 2016-08-13 | MAP | N | N | 330016730 | MAP |
| 330004227 | 330007138 | 0 | 60.9 | Curative (C) | 2016-01-11 | 2016-01-11 | DA 3 + 10 | N | N | 330016730 | DA |
| 330004228 | 330007138 | 1.72 | 71.9 | Curative (C) | 2017-08-08 | 2017-09-09 | CETUXIMAB | N | Y | 330016730 | CETUXIMAB |
| 330004229 | 330002082 | null | null | Palliative (P) | 2017-08-07 | 2017-08-08 | Cisplatin + Etoposide po&iv 3 day | N | N | 330016756 | CISPLATIN + ETOPOSIDE |
| 330004230 | 330002083 | 0 | 45.2 | Curative (C) | 2013-05-02 | 2013-05-17 | Cetuximab + Radiotherapy Load | N | Y | 330016757 | CETUXIMAB + RT |
| 330004231 | 330002083 | 1.67 | 75 | Curative (C) | 2016-01-07 | 2016-01-08 | DA 3 + 10 | N | N | 330016757 | DA |